Thesan Pharmaceuticals Adds $49M

San Diego-based Thesan Pharmaceuticals, which is developing treatments for acne and atopic dermatitis, said today that it has raised $49M in a Series B financing round. The funding round was led by Novo Ventures, and also included SV Life Sciences, Lundbeckfond Ventures, and Norvartis Venture Fund. Thesan, which is led by Gordon Foulkes, said that Michael Ross of SVLS and Mette Kirstine Agger from Lundbeckfond Ventures both join the company's board with the funding round. More information »